Novartis AG

SECUKINUMAB PROVIDES RAPID AND SUSTAINED RESOLUTION OF ENTHESITIS IN PSORIATIC ARTHRITIS PATIENTS: POOLED ANALYSIS OF TWO PHASE 3 STUDIES, FUTURE 2 AND FUTURE 3 (2018) Coates LC, Mcgonagle D, Schett G, Mease PJ, Quebe-Fehling E, Asquith DL, Rasouliyan L, et al. Conference contribution Individualised treatment targets in patients with type-2 diabetes and hypertension (2018) Schmieder R, Tschoepe D, Koch C, Ouarrak T, Gitt AK Journal article Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study (2018) Mcinnes IB, Mease PJ, Schett G, Kirkham B, Strand V, Williams N, Fox T, et al. Journal article Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent (2017) Richardson P, Roy A, Acharyya S, Panneerselvam A, Mendelson E, Guenther A, Lonial S, Einsele H Journal article Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial (2017) San-Miguel JF, Hungria VTM, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, et al. Journal article Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab (2017) Garcia-Guerrero E, Gogishvili T, Danhof S, Schreder M, Pallaud C, Perez-Simon JA, Einsele H, Hudecek M Journal article Efficacy and safety of nilotinib in patients with kit-mutated metastatic or inoperable melanoma: Final results from the global, single-arm, phase ii team trial (2017) Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, et al. Journal article Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency (2017) Lovric S, Goncalves S, Gee HY, Oskouian B, Srinivas H, Choi WI, Shril S, et al. Journal article Real world effectiveness and safety of pazopanib and everolimus in metastatic renal cell carcinoma: first interim analysis of the PAZOREAL study (2017) Bedke J, Welslau M, Boegemann M, Schostak M, Hering-Schubert C, Petzoldt A, Wolf T, et al. Conference contribution RECREATE - A retrospective chart review to assess the treatment reality for mRCC patients following 1st line Pazopanib: reflecting a changing mRCC treatment landscape (2017) Hegele A, Van Der Heyde E, Goebell P, Zengerling F, Hbner A, Klier J, Belz H, et al. Conference contribution